There are multiple smoking cessation products on the market. But there hasn't been a new approval of a pharmacotherapy without nicotine in nearly 20 years. This could change soon, as cytisinicline was ...

New research from Johns Hopkins Medicine adds to existing evidence that smoking fewer cigarettes does not eliminate cardiovascular disease risk, and quitting entirely is the most effective strategy ...

Adults from low-income populations who used a smartphone application that delivered tailored, real-time content quit smoking at much higher rates after about 6 months than those who received standard ...

Memory and verbal fluency declined at a significantly slower pace in people who quit smoking in mid‑to-late life compared to those who continued smoking, with cognitive benefits from quitting observed ...

In response to concerning statistics showing that smoking remains a leading cause of preventable death in the United States, claiming hundreds of thousands of lives annually, According to the American ...

Around 25% of people with cancer in the U.S. are active smokers when they are diagnosed, and studies have found that many of them continue to smoke during treatment. This may be due in part to a ...

ACHV's cytisinicline shows best-in-class efficacy and safety for smoking cessation, supported by strong clinical data and recent NDA submission. The target market is large, with millions seeking ...